Recombinant human EGF conjugated vaccine

癌症治疗用重组人表皮生长因子（EGF）偶联疫苗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human EGF conjugated vaccine
Drug Alias Namehu-rEGF-rP64k/Mont vaccine
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Conjugated vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryParaguayCubaPeru +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBiotech Pharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Jingyitaixiang Technology Development Co LtdBiotech Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeJ07X
Related LinksN/A